Novartis Highlights Early Data from Potential Lumakras Competitor at AACR

Novartis presented promising early clinical data for its JDQ443, a KRASG12C inhibitor, at the American Association for Cancer Research (ACCR) annual meeting. Although the data was preliminary from a Phase Ib trial, investors are already speculating that the drug - when and if it makes it to regulators - could compete with Amgen’s Lumakras (sotorasib).